New model pharma
With investor confidence in the biotech sector taking a massive hit in the wake of the recession, VCs are pushing a new approach to backing early-stage companies in a bid to win back support
1 November 2009•6 mins read
With investor confidence in the biotech sector taking a massive hit in the wake of the recession, VCs are pushing a new approach to backing early-stage companies in a bid to win back support
